RedHill Biopharma traded at $0.21 this Friday January 27th, increasing $0.03 or 14.01 percent since the previous trading session. Looking back, over the last four weeks, RedHill Biopharma gained 50.04 percent. Over the last 12 months, its price fell by 91.29 percent. Looking ahead, we forecast RedHill Biopharma to be priced at 0.17 by the end of this quarter and at 0.15 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Adamis Pharmaceuticals 0.20 0.002 0.82% -66.33%
Cara Therapeutics 12.20 -0.07 -0.57% 10.61%
Cronos Group Inc 3.29 0.05 1.54% -24.89%
Intra Cellular Therapies 48.48 -0.29 -0.59% 5.99%
RedHill Biopharma 0.21 0.03 14.01% -91.29%

Indexes Price Day Year
USND 11645 132.88 1.15% -15.43%

RedHill Biopharma
Redhill Biopharma Ltd is an Israel-basedis a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The Company promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.